28. February 2025 | Corporate News

Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals

  • All requirements for closing the deal, including shareholders’ approval and ending of the restructuring proceedings, have been met
  • Closing is associated with an upfront payment of EUR 5 million
  • Additionally, Marinomed and Unither entered into a transition service agreement

The full press release is available here:

Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals
(61 KB)